New approaches to the treatment of human herpesvirus 8-associated disease

Reviews in Medical Virology

Volumn 18, Issue 5, 2008, Pages 321-329

  Casper, Corey ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; IM 862; IMATINIB; INCYCLINIDE; INTERLEUKIN 6 ANTIBODY; MATRIX METALLOPROTEINASE; PENCICLOVIR; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SORAFENIB; VALGANCICLOVIR; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; VASCULOTROPIN;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIBIOTIC SENSITIVITY; ANTISENSE THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TREATMENT FAILURE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; INFECTION RISK; KAPOSI SARCOMA; LOW DRUG DOSE; MOLECULAR THERAPY; MONOTHERAPY; NONHUMAN; PHOTOSENSITIVITY; PREVALENCE; PRIMARY EFFUSION LYMPHOMA; RETINITIS; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; GANCICLOVIR; GIANT LYMPH NODE HYPERPLASIA; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; LYMPHOMA, PRIMARY EFFUSION; SARCOMA, KAPOSI;

EID: 52649093409     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.583     Document Type: Review

References (78)

1. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266(5192): 1865-1869.
2. Schulz TF. Epidemiology of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. Adv Cancer Res 1999; 76: 121-160.
3. Dukers NH, Rezza G. Human herpesvirus 8 epidemiology: what we do and do not know. AIDS 2003; 17(12): 1717-1730.
4. Biggar RJ, Whitby D, Marshall V, Linhares AC, Black F. Human herpesvirus 8 in Brazilian Amerindians: a hyperendemic population with a new subtype. J Infect Dis 2000; 181(5): 1562-1568.
5. Dilnur P, Katano H, Wang ZH, et al. Classic type of Kaposi's sarcoma and human herpesvirus 8 infection in Xinjiang, China. Pathol Int 2001; 51(11): 845-852.
6. Casper C, Carrell D, Miller KG, et al. HIV serodiscordant sex partners and the prevalence of human herpesvirus 8 infection among HIV negative men who have sex with men: baseline data from the EXPLORE Study. Sex Transm Infect 2006; 82(3): 229-235.
7. Koelle DM, Huang ML, Chandran B, Vieira J, Piepkorn M, Corey L. Frequent detection of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in saliva of human immunodeficiency virus-infected men: clinical and immunologic correlates. J Infect Dis 1997; 176(1): 94-102.
8. Pauk J, Huang ML, Brodie SJ, et al. Mucosal shedding of human herpesvirus 8 in men. N Engl J Med 2000; 343(19): 1369-1377.
9. Vieira J, Huang ML, Koelle DM, Corey L. Transmissible Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of men with a history of Kaposi's sarcoma. J Virol 1997; 71(9): 7083-7087.
10. Casper C, Krantz E, Selke S, et al. Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. J Infect Dis 2007; 195(1): 30-36.
11. Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med 2000; 342(14): 1027-1038.
12. International Union against Cancer, International Agency for Research on Cancer, International Association of Cancer Registries. Cancer incidence in five continents. Volume VIII. IARC Sci Publ, 2002; 155: 1-781.
13. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990; 335(8682): 123-128.
14. Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002; 94(16): 1204-1210.
15. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 2006; 118(12): 3030-3044.
16. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005; 129(1): 3-17.
17. Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 2004; 22(3): 399-402.
18. Nguyen HQ, Magaret AS, Van Rompaey SE, Kitahata MM, Wald A, Casper C. Persistent Kaposi sarcoma in the era of HAART: characterizing the predictors of clinical response. AIDS 2008; In Press.
19. Vanni T, Sprinz E, Machado MW, Santana Rde C, Fonseca BA, Schwartsmann G. Systemic treatment of AIDS-related Kaposi sarcoma: current status and perspectives. Cancer Treat Rev 2006; 32(6): 445-455.
20. Boulanger E, Gerard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005; 23(19): 4372-4380.
21. Laney AS, Dollard SC, Jaffe HW, et al. Repeated measures study of human herpesvirus 8 (HHV-8) DNA and antibodies in men seropositive for both HHV-8 and HIV. AIDS 2004; 18(13): 1819-1826.
22. Smith MS, Bloomer C, Horvat R, Goldstein E, Casparian JM, Chandran B. Detection of human herpesvirus 8 DNA in Kaposi's sarcoma lesions and peripheral blood of human immunodeficiency virus-positive patients and correlation with serologic measurements. J Infect Dis 1997; 176(1): 84-93.
23. Alagiozoglou L, Morris L, Bredell H, Martin DJ, Sitas F. Human herpesvirus-8 antibodies and DNA in HIV-1 infected patients in South Africa. Epidemiol Infect 2003; 131(3): 1125-1129.
24. Ziegler J, Newton R, Bourboulia D, et al. Risk factors for Kaposi's sarcoma: a case-control study of HIV-seronegative people in Uganda. Int J Cancer 2003; 103(2): 233-240.
25. Grundhoff A, Ganem D. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest 2004; 113(1): 124-136.
26. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 2000; 96(6): 2069-2073.
27. Katano H, Sato Y, Kurata T, Mori S, Sata T. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology 2000; 269(2): 335-344.
28. Schaeffer HJ, Beauchamp L, de Miranda P, Elion GB, Bauer DJ, Collins P. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 1978; 272(5654): 583-585.
29. Naesens L, De Clercq E. Recent developments in herpesvirus therapy. Herpes 2001; 8(1): 12-16.
30. Mercorelli B, Sinigalia E, Loregian A, Palu G. Human cytomegalovirus DNA replication: antiviral targets and drugs. Rev Med Virol 2008; 18(3): 177-210.
31. Cannon JS, Hamzeh F, Moore S, Nicholas J, Ambinder RF. Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J Virol 1999; 73(6): 4786-4793.
32. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997; 99(9): 2082-2086.
33. Medveczky MM, Horvath E, Lund T, Medveczky PG. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS 1997; 11(11): 1327-1332.
34. Neyts J, De Clercq E. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother 1997; 41(12): 2754-2756.
35. Friedrichs C, Neyts J, Gaspar G, Clercq ED, Wutzler P. Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay. Antiviral Res 2004; 62(3): 121-123.
36. Krug LT, Pozharskaya VP, Yu Y, Inoue N, Offermann MK. Inhibition of infection and replication of human herpesvirus 8 in microvascular endothelial cells by alpha interferon and phosphonoformic acid. J Virol 2004; 78(15): 8359-8371.
37. Dittmer D, Stoddart C, Renne R, et al. Experimental transmission of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) to SCID-hu Thy/ Liv mice. J Exp Med 1999; 190(12): 1857-1868.
38. Glesby MJ, Hoover DR, Weng S, et al, Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the multicenter AIDS cohort study. J Infect Dis 1996; 173(6): 1477-1480.
39. Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips AN. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal free/Chelsea and Westminster hospitals collaborative group. AIDS 1996; 10(10): 1101-1105.
40. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999; 340(14): 1063-1070.
41. Casper C, Krantz EM, Kuntz SR, et al. Valganciclovir for Suppression of human herpesvirus 8 (HHV-8) replication: a randomized, double-blind, placebo-controlled trial. J Infect Dis 2008; 198(1): 23-30.
42. Little RF, Merced-Galindez F, Staskus K, et al. A pilot study of cidofovir in patients with kaposi sarcoma. J Infect Dis 2003; 187(1): 149-153.
43. Krown SE, Lee JY, Lin L, Fischl MA, Ambinder R, Roenn JH. Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium Phase I trial. J Acquir Immune Defic Syndr 2006; 41(2): 149-153.
44. Crum-Cianflone NF, Wallace MR, Looney D. Successful secondary prophylaxis for primary effusion lymphoma with human herpesvirus 8 therapy. AIDS 2006; 20(11): 1567-1569.
45. Pastore RD, Chadburn A, Kripas C, Schattner EJ. Novel association of haemophagocytic syndrome with Kaposi's sarcoma-associated herpesvirus-related primary effusion lymphoma. Br J Haematol 2000; 111(4): 1112-1115.
46. Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS 2001; 15(2): 280-282.
47. Luppi M, Trovato R, Barozzi P, et al. Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia 2005; 19(3): 473-476.
48. Valencia ME, Moreno V, Martinez P, Casado I. [Favorable outcome of Castleman's disease treated with oral valganciclovir]. Med Clin (Barc) 2005; 125(10): 399.
49. Casper C, Nichols WG, Huang ML, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004; 103(5): 1632-1634.
50. Berezne A, Agbalika F, Oksenhendler E, et al. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood 2004; 103(01): 4368-4369.
51. Klass CM, Krug LT, Pozharskaya VP, Offermann MK. The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood 2005; 4028-4034.
52. Curreli F, Friedman-Kien AE, Flore O. Glycyrrhizic acid alters Kaposi sarcoma-associated herpesvirus latency, triggering p53-mediated apoptosis in transformed B lymphocytes. J Clin Invest 2005; 115(3): 642-652.
53. Brown HJ, McBride WH, Zack JA, Sun R. Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus. Antivir Ther 2005; 10(6): 745-751.
54. Dezube BJ, Sullivan R, Koon HB. Emerging targets and novel strategies in the treatment of AIDS-related Kaposi's sarcoma: bidirectional translational science. J Cell Physiol 2006; 209(3): 659-662.
55. Masood R, Cesarman E, Smith DL, Gill PS, Flore O. Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor. Am J Pathol 2002; 160(1): 23-29.
56. Bais C, Van Geelen A, Eroles P, et al. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell 2003; 3(2): 131-143.
57. Wang L, Wakisaka N, Tomlinson CC, et al. The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. Cancer Res 2004; 64(8): 2774-2781.
58. Pluda JM, Shay LE, Foli A, et al. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst 1993; 85(09): 1585-1592.
59. Schwartsmann G, Sprinz E, Kalakun L, et al. Phase II study of pentosan polysulfate (PPS) in patients with AIDS-related Kaposi's sarcoma. Tumori 1996, 82(4): 360-363.
60. Eckhardt SG, Burris HA, Eckardt JR, et al. A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Ann Oncol 1996; 7(5): 491-496.
61. Tulpule A, Scadden DT, Espina BM et al. Results of a randomized study of W862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18(4): 716-723.
62. Noy A, Scadden DT, Lee J, et al. Angiogenesis inhibitor IM862 Is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS malignancy consortium and IM862 study team. J. Clin Oncol 2005; 23(5): 990-998.
63. Levine AM, Tulpule A, Quinn DI, et al. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol 2006; 24(11): 1712-1719.
64. Moses AV, Jarvis MA, Raggo C, et al. Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol 2002; 76(16): 8383-8399.
65. Koon HB, Bubley GJ, Pantanowitz L, et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 2005; 23(5): 982-989.
66. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990; 86(2): 592-599.
67. Beck JT, Hsu SM, Wijdenes J, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994; 330(9): 602-605.
68. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005; 106(8): 2627-2632.
69. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2001; 98(12): 3473-3475.
70. Marcelin A-G, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman disease. Blood 2003; 102(8): 2786-2788.
71. Newsom-Davis T, Bower M, Wildfire A, et al. Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels. Leuk Lymphoma 2004; 45(9): 1939-1941.
72. Kofteridis DP, Tzagarakis N, Mixaki I, et al. Multicentric Castleman's disease: prolonged remission with anti CD-20 monoclonal antibody in an HIV-infected patient. AIDS 2004; 18(3): 585-586.
73. Ide M, Ogawa E, Kasagi K, Kawachi Y, Ogino T. Successful treatment of multicentric Castleman's disease with bilateral orbital tumour using rituximab. Br J Haematol 2003; 121(5): 818-819.
74. Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol 2003; 82(12): 766-768.
75. Lim ST, Rubin N, Said J, Levine AM. Primary effusion lymphoma: successful treatment with highly active antiretroviral therapy and rituximab. Ann Hematol 2005; 84(8): 551-552.
76. Matsumoto Y, Nomura K, Ueda K, et al. Human herpesvirus 8-negative malignant effusion lymphoma: a distinct clinical entity and successful treatment with rituximab. Leuk Lymphoma 2005; 46(3): 415-419.
77. Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007; 147(12): 836-839.
78. Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS malignancy consortium study. J Clin Oncol 2006; 24(9): 1389-1394.